Gleason Score News and Research

RSS

Researchers identify biomarker that can predict GS7 prostate cancer patients

Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker living next door to the KLK3 gene that can predict which GS7 prostate cancer patients will have a more aggressive form of cancer.

3 Oct 2014

Prostate biopsy method impacts cancer risk profile

Prostate cancers that are classified as “low risk” based on conventional prostate biopsy and histology are frequently found to be higher risk when assessed using the newer targeted biopsy method, US researchers have warned.

5 Jun 2014

ProMark test for prostate cancer meets primary endpoint

Today, for the first time, Metamark presents results from the clinical validation study that showed ProMark, the first and only proteomic-based imaging biopsy test, achieved its primary endpoint by accurately differentiating between aggressive and non-aggressive forms of prostate cancer at early stages of disease.

2 Jun 2014

Vitamin D deficiency predicts prostate biopsy outcomes

Men with vitamin D deficiency are more likely than men with normal levels to test positive for prostate cancer on biopsy, and to have aggressive disease, US researchers have found.

28 May 2014

Men with chronic inflammation in non-cancerous prostate tissue may have nearly twice risk of prostate cancer

Men who show signs of chronic inflammation in non-cancerous prostate tissue may have nearly twice the risk of actually having prostate cancer than those with no inflammation, according to results of a new study led by researchers from the Johns Hopkins Kimmel Cancer Center.

18 Apr 2014

Invasive 3D mapping biopsies detect ultrasound-guided biopsies miss prostate cancers

Ultrasound-guided biopsies miss prostate cancers that are detected by the slightly more expensive and slightly more invasive 3D mapping biopsies. For example, in a 2006 study of 180 men diagnosed with early stage prostate cancer via ultrasound-guided biopsy, nearly a quarter were upgraded to a more clinically significant stage of disease after 3D mapping biopsy found pockets of cancer the first technique had missed.

5 Feb 2014

Myriad Genetics' Prolaris opens door to a new era of personalized treatment for prostate cancer

Myriad Genetics, Inc. today announced results from PROCEDE 500, a clinical utility study with its Prolaris test, at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, Calif. The study demonstrated the significant clinical value of Prolaris to physicians who are treating men with prostate cancer. Prolaris is a prognostic test that accurately predicts prostate cancer-specific death and metastases and has been validated in 11 clinical studies with more than 5,000 patients.

29 Jan 2014

Nomogram predicts overdiagnosis in prostate cancer screening

US researchers have developed a nomogram which they say can be used to predict whether prostate cancer has been overdiagnosed in individual patients diagnosed following prostate-specific antigen screening.

20 Jan 2014

Higher levels of physical activity reduces risk of prostate cancer recurrence, mortality

Men who walked at a fast pace prior to a prostate cancer diagnosis had more regularly shaped blood vessels in their prostate tumors compared with men who walked slowly, providing a potential explanation for why exercise is linked to improved outcomes for men with prostate cancer, according to results presented here at the AACR-Prostate Cancer Foundation Conference on Advances in Prostate Cancer Research, held Jan. 18-21.

20 Jan 2014

Researchers develop personalized tool to predict likelihood of prostate cancer overdiagnosis

Studies have found that prostate cancer is overdiagnosed in up to 42 percent of cases, prompting men to receive unnecessary treatment that can cause devastating side effects, including impotence and incontinence.

9 Jan 2014

Perioperative analgesia may improve prostate cancer outcomes

Neuraxial analgesia added to general anesthesia for radical retropubic prostatectomy may lead to improved oncologic outcomes in prostate cancer, US researchers have found.

6 Jan 2014

Treatment of pelvic nodes can be easily integrated into IMRT-based treatment strategy

Treatment of pelvic nodes individualized by inclusion of sentinel nodes can be easily integrated into an IMRT-based treatment strategy, according to the new study conducted by a group of researchers from T-bingen and Munich in Germany. The target volume concept seems to correctly cover individual pelvic nodes, which is indicated by the absence of any nodal recurrence within five years of follow-up.

18 Nov 2013

Overweight men diagnosed with prostate cancer more likely to die from the disease

Men who are overweight or obese when they are diagnosed with prostate cancer are more likely to die from the disease than men who are of healthy weight, according to a Kaiser Permanente study published today in the journal Obesity Research & Clinical Practice. In patients with more aggressive forms of prostate cancer, the researchers also found an even stronger correlation between obesity and mortality.

30 Oct 2013

PSA mass ratio shows prognostic power in localized prostate cancer

Research shows that pathologic prostate-specific antigen mass ratio is a significant predictor for biochemical recurrence-free survival following radical prostatectomy for localized prostate cancer in patients with negative surgical resection margins.

8 Oct 2013

Tool guides lymph node surgery in Asian prostate cancer patients

Researchers from Korea have developed a nomogram that predicts which Asian men with prostate cancer are most at risk for lymph node (LN) invasion.

30 Sep 2013

Length of telomere may help determine prostate cancer patient's prognosis

Like the plastic caps at the end of shoelaces, telomeres protect — in their case — the interior-gene containing parts of chromosomes that carry a cell's instructional material. Cancer cells are known to have short telomeres, but just how short they are from cancer cell to cancer cell may be a determining factor in a prostate cancer patient's prognosis, according to a study led by Johns Hopkins scientists.

27 Sep 2013

New ultra-specific test now available for prostate cancer

A new urine test for prostate cancer that measures minute fragments of RNA is now commercially available to men nationwide through the University of Michigan MLabs.

27 Sep 2013

Long-term hormonal therapy has no additional benefits in men with intermediate-risk prostate cancer

A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

24 Sep 2013

Gene panel predicts low-risk prostate cancer fate

Researchers from the USA have identified a three-gene signature that can predict prostate cancer progression in low Gleason score tumors.

16 Sep 2013

Three-gene biomarker can help determine treatment option for early prostate cancer

The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow-growing, according to researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center.

13 Sep 2013